Increased serum kallistatin levels in type 1 diabetes patients with vascular complications

Journal of Angiogenesis Research

Volumn 2, Issue 1, 2010, Pages

  Jenkins, Alicia J ^a,b   Januszewski, Andrzej S ^a   Karschimkus, Connie S ^a   Zhang, Bin ^b,c   O'Neal, David N ^a   Nelson, Craig L ^a   Chung, Jasmine S ^a   Harper, C Alex ^a   Lyons, Timothy J ^b   Ma, Jian Xing ^b,c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^c UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BILIRUBIN; C REACTIVE PROTEIN; CHOLESTEROL; CREATININE; CYSTATIN C; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERCELLULAR ADHESION MOLECULE 1; KALLISTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGE DISTRIBUTION; ARTICLE; BILIRUBIN BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; CROSS-SECTIONAL STUDY; ELASTICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DISEASE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; UREA BLOOD LEVEL; VASCULAR DISEASE;

EID: 77957869495     PISSN: None     EISSN: 20402384     Source Type: Journal    
DOI: 10.1186/2040-2384-2-19     Document Type: Article

References (47)

1. Lipoproteins, glycoxidation and diabetic angiopathy. AJ Jenkins JD Best RL Klein TJ Lyons, Diabetes Metab Res Rev 2004 20 349 368 10.1002/dmrr.491 15343582
2. Diabetic retinopathy and angiogenesis. TN Crawford DV Alfaro JB Kerrison EP Jablon, Curr Diabetes Rev 2009 5 1 8 13 10.2174/157339909787314149 19199892
3. Down-regulation of angiogenic inhibitors: a potential pathogenic mechanism for diabetic complications. JX Ma SX Zhang JJ Wang, Curr Diabetes Rev 2005 1 2 183 196 10.2174/1573399054022839 18220594
4. Vascular endothelial growth factor and diabetic nephropathy. S Chen FN Ziyadeh, Curr Diab Rep 2008 8 6 470 476 10.1007/s11892-008-0081-3 18990304
5. Angiogenesis in atherosclerosis: gathering evidence beyond speculation. KS Moulton, Curr Opin Lipidol 2006 17 5 548 555 10.1097/01.mol.0000245261.71129. f0 16960504
6. Plaque angiogenesis versus compensatory arteriogenesis in atherosclerosis. CH Chen JP Walterscheid, Circ Res 2006 99 8 787 789 10.1161/01.RES.0000247758.34085.a6 17038645
7. Novel roles of kallistatin, a specific tissue kallikrein inhibitor, in vascular remodeling. J Chao RQ Miao V Chen LM Chen L Chao, Biol Chem 2001 382 1 15 21 10.1515/BC.2001.003 11258665
8. Kallistatin is a new inhibitor of angiogenesis and tumor growth. RQ Miao J Agata L Chao J Chao, Blood 2002 100 9 3245 3252 10.1182/blood-2002-01-0185 12384424
9. Novel role of kallistatin in protection against myocardial ischemia-reperfusion injury by preventing apoptosis and inflammation. J Chao H Yin YY Yao B Shen RS Smith Jr L Chao, Hum Gene Ther 2006 17 12 1201 1213 10.1089/hum.2006.17.1201 17081080
10. Kallistatin is a potent new vasodilator. J Chao JN Stallone YM Liang LM Chen DZ Wang L Chao, J Clin Invest 1997 100 1 11 17 10.1172/JCI119502 9202051
11. Role of kallistatin in prevention of cardiac remodeling after chronic myocardial infarction. L Gao H Yin R S Smith Jr L Chao J Chao, Lab Invest 2008 88 11 1157 1166 10.1038/labinvest.2008.85 18762777
12. Salutary effect of kallistatin in salt-induced renal injury, inflammation, and fibrosis via antioxidative stress. B Shen M Hagiwara YY Yao L Chao J Chao, Hypertension 2008 51 5 1358 1365 10.1161/HYPERTENSIONAHA.107.108514 18391098
13. Kallistatin stimulates vascular smooth muscle cell proliferation and migration in vitro and neointima formation in balloon-injured rat artery. RQ Miao H Murakami Q Song L Chao J Chao, Circ Res 2000 86 4 418 424 10700446
14. Kallistatin, a novel human tissue kallikrein inhibitor: levels in body fluids, blood cells, and tissues in health and disease. J Chao A Schmaier LM Chen Z Yang L Chao, J Lab Clin Med 1996 127 6 612 620 10.1016/S0022-2143(96) 90152-3 8648266
15. Localization and expression of tissue kallikrein and kallistatin in human blood vessels. WC Wolf RA Harley D Sluce L Chao J Chao, J Histochem Cytochem 1999 47 2 221 228 9889257
16. Kallikrein-binding protein levels are reduced in the retinas of streptozotocin-induced diabetic rats. HC Hatcher JX Ma J Chao L Chao A Ottlecz, Invest Ophthalmol Vis Sci 1997 38 3 658 664 9071220
17. Kallistatin in human ocular tissues: reduced levels in vitreous fluids from patients with diabetic retinopathy. JX Ma LP King Z Yang RK Crouch L Chao J Chao, Curr Eye Res 1996 15 11 1117 1123 10.3109/02713689608995143 8950506
18. Strategies for blocking angiogenesis in diabetic retinopathy: from basic science to clinical practice. C Hernndez R Simá Expert Opin Investig Drugs 2007 16 8 1209 1226 10.1517/13543784.16.8.1209 17685870
19. Comparison of arterial assessments in low and high vascular disease risk groups. AM Wilson D O'Neal CL Nelson DL Prior JD Best AJ Jenkins, Am J Hypertens 2004 17 285 291 10.1016/j.amjhyper.2003.10.009 15062880
20. Systemic and vascular inflammation is elevated in early IgA and type 1 diabetic nephropathies and relates to vascular disease risk factors and renal function. CL Nelson CS Karschimkus G Dragicevic DK Packham AM Wilson D O'Neal GJ Becker JD Best AJ Jenkins, Nephrol Dial Transplant 2005 20 2420 2426 10.1093/ndt/gfi067 16115854
21. Traditional risk factor assessment does not capture the extent of cardiovascular risk in systemic lupus erythematosus. AB Lee T Godfrey KG Rowley CS Karschimkus G Dragicevic E Romas L Clemens AM Wilson M Nikpour DL Prior JD Best AJ Jenkins, Intern Med J 2006 36 4 237 243 10.1111/j.1445-5994.2006.01044.x 16640741
22. Reduced arterial elasticity in rheumatoid arthritis and the relationship to vascular disease risk factors and inflammation. M Wong L Toh A Wilson K Rowley C Karschimkus D Prior E Romas L Clemens G Dragicevic H Harianto I Wicks G McColl J Best A Jenkins, Arthritis Rheum 2003 48 1 81 89 10.1002/art.10748 12528107
23. Increased serum pigment epithelium-derived factor is associated with microvascular complications, vascular stiffness and inflammation in Type 1 diabetes. AJ Jenkins SX Zhang KG Rowley CS Karschimkus CL Nelson JS Chung DN O'Neal AS Januszewski KD Croft TA Mori G Dragicevic CA Harper JD Best TJ Lyons JX Ma, Diabet Med 2007 24 12 1345 1351 10.1111/j.1464-5491.2007.02281.x 17971181
24. Clinical practice guidelines for chronic kidney disease in adults: Part II. Glomerular filtration rate, proteinuria, and other markers. CA Johnson AS Levey J Coresh A Levin J Lau G Eknoyan, Am Fam Physician 2004 70 1091 1097 15456118
25. Biochemistry, regulation and potential function of kallistatin. J Chao L Chao, Biol Chem Hoppe Seyler 1995 376 12 705 713 9072045
26. Renal and urinary proteomics: current applications and challenges. V Thongboonkerd P Malasit, Proteomics 2005 5 4 1033 1042 10.1002/pmic.200401012 15669002
27. Cellular localization of tissue kallikrein and kallistatin mRNAs in human kidney. LM Chen Q Song L Chao J Chao, Kidney Int 1995 48 3 690 697 10.1038/ki.1995.339 7474653
28. The tissue kallikrein-kinin system protects against cardiovascular and renal diseases and ischemic stroke independently of blood pressure reduction. J Chao G Bledsoe H Yin L Chao, Biol Chem 2006 387 6 665 675 10.1515/BC.2006.085 16800727
29. Diabetic nephropathy is associated with increased albumin and fibrinogen production in patients with type 2 diabetes. P Tessari E Kiwanuka R Barazzoni M Vettore M Zanetti, Diabetologia 2006 49 8 1955 1961 10.1007/s00125-006-0288-2 16703327
30. Tissue kallikrein-binding protein reduces blood pressure in transgenic mice. L-M Chen J-X Ma Y-M Liang L Chao J Chao, J Biol Chem 1996 271 27590 27594 10.1074/jbc.271.44.27590 8910346
31. Adenoviral-mediated delivery of human kallistatin gene reduces blood pressure of spontaneously hypertensive rats. L-M Chen L Chao J Chao, Hum Gene Ther 1997 8 341 347 10.1089/hum.1997.8.3-341 9048201 (Pubitemid 27412270)
32. Beneficial effects of kallikrein-binding protein in transgenic mice during endotoxic shock. L-M Chen L Chao J Chao, Life Sci 1996 60 1431 1436 10.1016/S0024-3205(97)00094-5
33. Cross-sectional associations of C-reactive protein with vascular risk factors and vascular complications in the DCCT/EDIC cohort. AJ Jenkins M Rothen RL Klein K Moller L Eldridge D Zheng R Durazo-Arvizu D McGee D Lackland SR Thorpe WT Garvey TJ Lyons DCCT/EDIC Research Group, J Diabetes Complications 2008 22 3 153 163 10.1016/j.jdiacomp.2007.02.003 18413218
34. Risk factors related to inflammation and endothelial dysfunction in the DCCT/EDIC cohort and their relationship with nephropathy and macrovascular complications. MF Lopes-Virella RE Carter GE Gilbert RL Klein M Jaffa AJ Jenkins TJ Lyons WT Garvey G Virella Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications Cohort Study Group, Diabetes Care 2008 31 10 2006 2012 10.2337/dc08-0659 18628568
35. Upregulation of kallistatin expression in rheumatoid joints. CR Wang SY Chen AL Shiau CL Wu IM Jou L Chao J Chao, J Rheumatol 2007 34 11 2171 2176 17937475
36. Prophylactic adenovirus-mediated human kallistatin gene therapy suppresses rat arthritis by inhibiting angiogenesis and inflammation. CR Wang SY Chen CL Wu MF Liu YT Jin L Chao J Chao, Arthritis Rheum 2005 52 1319 1324 10.1002/art.20991 15818689
37. Tissue kallikrein in severe acute pancreatitis in patients treated with high-dose ntraperitoneal aprotinin. M Bläckberg R Berling K Ohlsson, Pancreas 1999 19 4 325 334 10.1097/00006676-199911000-00002 10547191
38. Expression of kallikrein-bonding protein and 1-antitrypsin genes in response to sex hormones, growth, inflammation and hypertension. J Chao LM Chen KX Chai L Chao, Agents Actions Suppl 1992 174 181 1466268
39. Beneficial effects of kallikrein-binding protein in transgenic mice during endotoxic shock. LM Chen L Chao J Chao, Life Sci 1997 60 1431 1435 10.1016/S0024-3205(97)00094-5 9126863
40. Therapeutic angiogenesis in cardiovascular disease. H Al Sabti, J Cardiothorac Surg 2007 2 49 10.1186/1749-8090-2-49 18021404
41. Angiogenesis as risk factor for plaque vulnerability. R Di Stefano F Felice A Balbarini, Curr Pharm Des 2009 15 10 1095 1106 10.2174/ 138161209787846892 19355951
42. Angiogenesis and inflammation in carotid atherosclerosis. J Krupinski A Font A Luque M Turu M Slevin, Front Biosci 2008 13 6472 6482 10.2741/3167 18508673
43. Inflammatory angiogenesis in atherogenesis - a double-edged sword. D Ribatti F Levi-Schaffer PT Kovanen, Ann Med 2008 40 8 606 621 10.1080/07853890802186913 18608127
44. Growth factor therapy in atherosclerotic disease-friend or foe. IE Hoefer L Timmers JJ Piek, Curr Pharm Des 2007 13 17 1803 1810 10.2174/ 138161207780831257 17584109
45. Controlled release systems of angiogenic growth factors for cardiovascular diseases. J Esaki A Marui Y Tabata M Komeda, Expert Opin Drug Deliv 2007 4 6 635 649 10.1517/17425247.4.6.635 17970666
46. New VEGF antagonists as possible therapeutic agents in vascular disease. M Slevin P Kumar Q Wang S Kumar J Gaffney M Grau-Olivares J Krupinski, Expert Opin Investig Drugs 2008 17 9 1301 1314 10.1517/13543784.17.9.1301 18694364
47. PEDF in angiogenic eye diseases. J Tombran-Tink, Curr Mol Med 2010 10 3 267 278 10.2174/156652410791065336 20236057